Though India does not deem non-compliance to good manufacturing practices (GMP) a case of adulteration,facilities of pharma major Ranbaxy are under the scanner after the company faced flak in the US for non-adherence to GMP.
Health Minister Ghulam Nabi Azad said this in Rajya Sabha Tuesday.
Ranbaxy USA Inc recently admitted in the US District Court of Maryland to manufacturing and distribution of certain drugs not in conformity with GMP and agreed to pay a fine of $500 million.
Drugs Controller General of India had been ordered to review facilities of Ranbaxy in the country to ascertain the quality of drugs manufactured for the domestic market,Azad said.
As per US law,a drug is considered adulterated if it is not manufactured,processed and packed in conformity with the Current Good Manufacturing Practice regulations of the USFDA, he said.